copanlisib + metformin

**Copanlisib + metformin** is an investigational combination of two drugs: copanlisib, an intravenous pan-class I PI3K inhibitor primarily active against PI3K-α and PI3K-δ isoforms, and metformin, a widely used oral biguanide antihyperglycemic agent for treating type 2 diabetes. - **Copanlisib** selectively inhibits phosphatidylinositol 3-kinase (PI3K) activity, leading to interruption of the PI3K/AKT/mTOR signaling pathway, which is implicated in the progression of several cancers, especially B-cell lymphomas[2][5][6]. - **Metformin** decreases hepatic glucose production and increases insulin sensitivity primarily by activation of AMP-activated protein kinase (AMPK). The combination is mainly of research interest regarding potential pharmacokinetic interactions, as copanlisib transiently increases plasma glucose and can cause hyperglycemia, which may be managed by glucose-lowering drugs like metformin[3][1]. There is no established therapeutic indication for the fixed combination beyond copanlisib’s approved use in relapsed follicular lymphoma and metformin’s use in diabetes[1][2][5][3].

Brand names

copanlisib + metformin

Other names

copanlisib + metformin